focus -WSS

focus

author：comprehensive 2025-09-03 07:50:29 - browse：23

Empty biotech lab with no people and green benches and cabinets. -- biotech coverage from STAT — Adobe

Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve been in a decade amid the biotech industry’s ongoing downturn, according to a report released Tuesday by Jones Lang LaSalle, a commercial real estate services company

Tenant demand, measured by the total amount of new space that companies are looking to lease, dropped from 25.3 million square feet at the end of 2021 to 10.1 million square feet by the second quarter of this year across eight top life science markets: Boston, the Bay Area, San Diego, Raleigh-Durham, Philadelphia, Seattle, Los Angeles, and the Washington, D.C., area.

The real estate numbers presented in JLL’s annual life sciences report are yet another sign that the biotech industry, which outperformed the broader market for years, is in the midst of a slowdown. Lab space is increasingly going unused amid a supply glut, and more companies are looking to sublease space. Real estate observers say there are some signs these trends could turn around in the next year or two, though that is far from certain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： The SUPPORT Act is critical to fighting the opioid crisis

WSS

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Beware reading your test results before your doctor does

The SUPPORT Act is critical to fighting the opioid crisis

Idaho abortion case may prompt more restrictions in other states

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

focus

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

As demand for Covid shots wanes, Moderna seeks its next success

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

At least 13 dead in Texas as scorching temps continue

Use doctors trained outside the U.S. to ease the physician shortage

Medicare proposal to cover medical devices draws a mixed reaction

The SUPPORT Act is critical to fighting the opioid crisis

DIEP, the 'gold standard' of breast reconstruction, is under threat

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

Health and fitness trackers are measuring the wrong things

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Undocumented workers face uncertainty as immigration law takes effect in Florida

Fauci’s Covid grilling leads GOP to weigh foreign research rules

GSK to buy asthma

Three issues to watch in global health in 2024

leisure time

leisure time

focus

focus